Skip to main content
Clinical Trials/ACTRN12613000439741
ACTRN12613000439741
Not yet recruiting
Phase 4

A clinical and electrophysiological study of the effects of 4-aminopyridine on upper limb impairment in Multiple Sclerosis

Austin Health0 sites30 target enrollmentApril 17, 2013

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Multiple Sclerosis
Sponsor
Austin Health
Enrollment
30
Status
Not yet recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 17, 2013
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients with multiple sclerosis who are currently taking modified release fampridine 10mg bd and who are willing to stop the drug for at least 10 days in order to permit measurements to be taken and compared on and off drug; preserved cognitive function permitting informed consent for participation.

Exclusion Criteria

  • The following are contraindications to fampridine therapy: history of seizures or epilepsy; hypersensitivity to fampridine; moderate/severe renal impairment; pregnancy; current or recent (60 days) MS relapse; alternative likely cause for upper limb impairment (e.g. peripheral neuropathy, injury); current or recent (60 days) therapy with corticosteroids; current therapy with benzodiazepines; recent (within 60 days) addition of new therapy for multiple sclerosis including disease\-modifying therapies and symptomatic therapies.

Outcomes

Primary Outcomes

Not specified

Similar Trials